"Among melanoma patients treated with the PD-1 inhibitor MK-3475, those whose tumors had the protein PD-L1 had better immune responses and higher survival rates, according to results presented here at the AACR Annual Meeting 2014, April 5-9.
"When the protein PD-L1, which is present on some melanoma tumors, binds to PD-1, a protein present on T cells, "brakes" are applied on these T cells, preventing them from attacking the cancer cells. The immunotherapy MK-3475 blocks PD-1, releasing the brakes on T cells and enabling them to attack the cancer cells."
Editor's note: This story is about a drug called MK-3475 (aka lambrolizumab), which boosts a patient's own immune system to fight cancer. It has shown promising results in clinical trials. Learn more about MK-3475 in this blog post.